window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Thalia Therapeutics acquires Sanmirna and raises £2.75M to advance AML RNA therapy

    Thalia Therapeutics has agreed a Sanmirna acquisition and £2.75m fundraise [...]

    June 25, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Meteor Biotech joins South Korea consortium to advance brain organoid commercialisation platform

    Meteor Biotech has joined a South Korean government-backed consortium aimed [...]

    June 23, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    TRIMTECH raises $14M to advance protein degradation therapies for neurodegenerative diseases

    TRIMTECH Therapeutics has secured an additional $14 million in seed [...]

    June 23, 2026
  • Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Therapeutic Areas

    Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness

    Atsena Therapeutics has dosed the first patient in the Phase [...]

    June 22, 2026
  • Advanced Therapies

    Houdini Bio develops DNA design platform targeting gene therapy silencing

    Houdini Bio has launched a machine learning-guided DNA sequence design [...]

    June 19, 2026
  • Advanced Therapies,Drug Discovery & Development

    Spot Biosystems reports early clinical evidence for non-viral dystrophin delivery in Duchenne muscular dystrophy

    Spot Biosystems has emerged from stealth with $40 million in [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business

    OrganaBio expands European access to perinatal and blood-derived research materials through Bio-Connect partnership

    OrganaBio has expanded access to its perinatal and peripheral blood-derived [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Genomics and sequencing,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scribe Therapeutics secures $25M CIRM backing to advance CRISPR cardiometabolic therapies

    Scribe Therapeutics has secured more than $25 million in CIRM [...]

    June 18, 2026
  • Advanced Therapies,Opinion & Events

    AMM and SRT partner to expand ASCENT 2026 RNA therapeutics programme

    The Alliance for mRNA Medicines (AMM) and the Society for [...]

    June 18, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Resolution Therapeutics expands regenerative macrophage pipeline with in vivo mRNA programme

    Resolution Therapeutics has expanded its regenerative macrophage therapy pipeline with [...]

    June 18, 2026
Previous456Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CluePoints brings AI-powered clinical data review to DPHARM 2026
    Categories: Clinical & Regulatory, Digital & Data, Research & Development
  • NVision deploys quantum-enhanced MRI platform at Hokkaido University
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • L-glutamine shows 44% response rate in Phase 1 pancreatic cancer trial
    Categories: Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top